脓毒症诱导的免疫抑制治疗的研究进展  

Research progress on treatments of immunosuppression induced by sepsis

作　　者：邹晗 钱何布[1] 赵宏胜[2] Zou Han;Qian Hebu;Zhao Hongsheng(Department of Intensive Care Unit,Affiliated Wujiang Hospital of Nantong University,Suzhou 215200,China;Department of Intensive Care Unit,Affiliated Hospital of Nantong University,Nantong 226000,China2)

机构地区：[1]南通大学附属吴江医院重症医学科,215200 [2]南通大学附属医院重症医学科,226000

出　　处：《中华重症医学电子杂志》2020年第4期453-456,共4页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

摘　　要：脓毒症目前仍然是全世界ICU入院和死亡的主要原因。近来免疫紊乱在脓毒症的发病机制中所起的关键作用及其不良的预后导致了人们对免疫治疗越来越感兴趣。最近的研究表明脓毒症患者的免疫反应存在异质性,部分表现为免疫抑制。目前能帮助机体在脓毒症期间恢复体内平衡的新型免疫调节治疗药物及方法可能是新的解决方案。本文综述了目前脓毒症出现免疫抑制时的治疗的最新研究进展。Sepsis remains the leading cause of admission and death in ICU worldwide.Recently,the key role and related poor prognosis of immune disorders in sepsis have drewmore and more interest to immunotherapy.Recent studies have shown heterogeneity in the immune responses in patients with sepsis.Some patients have immunosuppression.New immunoregulatory drugs and methods that can help restore homeostasis during sepsis may be solutions.This article reviews the most recent progress on the treatment of immunosuppressionin sepsis.

关 键 词：脓毒症 免疫抑制 综述 

分 类 号：R459.7[医药卫生—急诊医学]